SCHEMBL16445815

SCHEMBL16445815

FC1(F)CN(c2c[c]ccn2)C1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.31
PROKR1 Q8TCW9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20898786 0.79 ALDH1A1 (0.31) LRRK2
SCHEMBL20899088 0.77 ALDH1A1 (0.33)
SCHEMBL1599784 0.75 HRH4 (0.38)
SCHEMBL4831454 0.75 HRH4 (0.34)
SCHEMBL4829515 0.75
SCHEMBL2324452 0.73 HRH4 (0.40)
SCHEMBL20899052 0.71 LRRK2 (0.37) LRRK2
SCHEMBL16446455 0.70 PROKR1 (0.33) PROKR1
SCHEMBL455110 0.70 PIK3CA (0.44) LRRK2
SCHEMBL182823 0.70 PLD1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10160745-B2 Piperidine and azepine derivatives as prokineticin receptor modulators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-12-25 US disclosed
US-20180009780-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA PHARMACEUTICALS CO (JP) 2018-01-11 US disclosed
EP-3030553-B1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA PHARMACEUTICALS CO (JP) 2018-01-03 EP disclosed
US-9790201-B2 Piperidine and azepine derivatives as prokineticin receptor modulators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-17 US disclosed
US-20160185752-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-30 US disclosed
EP-3030553-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS Takeda Pharmaceutical Company Limited (JP) 2016-06-15 EP disclosed
WO-2015019103-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS TAKEDA CAMBRIDGE LIMITED (GB) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160745-B2 Piperidine and azepine derivatives as prokineticin receptor modulators GIPR, PROKR1, PROKR2 LRRK2 1861/4885PROKR1 2/4885
US-20160185752-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS GIPR, PROKR1, PROKR2 LRRK2 1804/4885PROKR1 2/4885
US-20180009780-A1 PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS GIPR, PROKR1, PROKR2 LRRK2 1861/4885PROKR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.